Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for MoonLake Immunotherapeutics's EV-to-OCF or its related term are showing as below:
MLTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.85 Med: 0 Max: -5.85
Current: -5.85
During the past 5 years, the highest EV-to-OCF of MoonLake Immunotherapeutics was -5.85. The lowest was -5.85. And the median was .
MLTX's EV-to-OCF is ranked better than 60.57% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs MLTX: -5.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MoonLake Immunotherapeutics's PE Ratio (TTM) for today is calculated as:
MoonLake Immunotherapeutics's share price for today is $18.45.
MoonLake Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MoonLake Immunotherapeutics EV-to-OCF Related Terms
MoonLake Immunotherapeutics EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MoonLake Immunotherapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's EV-to-OCF falls into.
MoonLake Immunotherapeutics's current Enterprise Value is $1,312.27 Mil.
MoonLake Immunotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-224.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics (MLTX) has a EV-to-OCF of -5.85 as of Aug. 01, 2026. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #556 out of 1410 companies in the Biotechnology industry, placing it in the top 39.4%.
Is MoonLake Immunotherapeutics' EV-to-OCF too high?
MoonLake Immunotherapeutics' current EV-to-OCF is -5.85. Based on the distribution chart, MoonLake Immunotherapeutics ranks #556 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' EV-to-OCF compare to TSHA and INVA?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #556 out of 1410 companies for EV-to-OCF. This puts MoonLake Immunotherapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. MoonLake Immunotherapeutics's current EV-to-OCF is -5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current EV-to-OCF of -5.85. The current EV-to-OCF is -5.85. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current EV-to-OCF is -5.85 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score
Get the complete analysis for MLTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLTX has been successfully added to your 
